Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study

[1]  D. Katsaros,et al.  Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer , 2007, Oncology.

[2]  M. Gore,et al.  Mucinous ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[3]  E. Eisenhauer,et al.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Katsaros,et al.  0009: Extending the Platinum-Free Interval (PFI) with a Non-Platinum Therapy in Platinum (P)-Sensitive Recurrent Ovarian Cancer (Oc): Results From the Socrates Retrospective Study , 2006, International Journal of Gynecologic Cancer.

[5]  H. Kajiyama,et al.  Clinical characteristics and prognosis of mucinous tumors of the ovary. , 2006, Gynecologic oncology.

[6]  G. Omura.  Re: Mucinous ovarian cancer. , 2005, Gynecologic oncology.

[7]  D. Farmakis,et al.  Reply to Prof. George Omura , 2005 .

[8]  K. Tamussino,et al.  Comment on "pregnancy after radical vaginal trachelectomy: maybe not such a risky undertaking after all". , 2005, Gynecologic oncology.

[9]  E. Trimble,et al.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Pignata,et al.  Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. , 2005, Anticancer research.

[11]  M. Dimopoulos,et al.  Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. , 2005, Gynecologic oncology.

[12]  M. Gore,et al.  Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[14]  C. Denkert,et al.  Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. , 2002, The American journal of pathology.

[15]  A. Whittemore,et al.  Survival among U.S. women with invasive epithelial ovarian cancer. , 2002, Gynecologic oncology.

[16]  R. Kreienberg,et al.  Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  O. Ishiko,et al.  Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. , 2001, International journal of molecular medicine.

[18]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[19]  A. Villanueva,et al.  K‐ras mutations in mucinous ovarian tumors , 1997, Cancer.

[20]  H E Lambert,et al.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Inoue,et al.  K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. , 1991, The American journal of pathology.

[22]  E. Yordan,et al.  Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  R. Burger,et al.  In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. , 2004, Gynecologic oncology.

[25]  E. Eisenhauer,et al.  Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. , 2003, Lancet.

[27]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[28]  M. Miwa,et al.  Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. , 1994, Cancer research.